Journal
CANCER BIOLOGY & THERAPY
Volume 13, Issue 12, Pages 1175-1184Publisher
LANDES BIOSCIENCE
DOI: 10.4161/cbt.21347
Keywords
mesenchymal stem cells; lentiviral; TRAIL; cisplatin; hepatocellular carcinoma; synergistic effect; bioluminescence imaging
Categories
Funding
- Joint Funds of the National Natural Science Foundation of China
- Government of Guangdong Province [U1032002]
- National Natural Science Foundation of China [81071206, 81172193]
- Team Project of Natural Science Foundation of Guangdong Province [05200177]
- Sci-Tech Project Foundation of Guangdong Province [2009B030801026]
Ask authors/readers for more resources
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been demonstrated to induce cell apoptosis in many types of tumors, while many hepatocellular carcinoma (HCC) cells display high resistance to TRAIL. Another outstanding limitation of TRAIL is the short half-life in vivo. Stem cell-based therapies provide a promising approach for the treatment of many types of tumors because of the ability of tropism. Therefore, as a new therapeutic strategy, the combination of chemotherapeutic agents and TRAIL gene modified MSCs (TRAIL-MSCs) would improve the therapeutic efficacy of HCC in vivo. This is the first time to show the potential of combination of chemotherapeutic agents and MSCs as a gene vector in the therapy of HCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available